InicioEVGN • NASDAQ
add
Evogene Ltd
Cierre anterior
0,94 $
Intervalo diario
0,93 $ - 1,10 $
Intervalo anual
0,93 $ - 2,42 $
Cap. bursátil
9,58 M USD
Volumen medio
55,63 mil
Relación precio-beneficio
-
Rentabilidad por dividendo
-
Bolsa de valores principal
NASDAQ
En las noticias
Datos financieros
Estado de resultados
Ingresos
Ingresos netos
| (USD) | sept 2025info | Cambio interanual |
|---|---|---|
Ingresos | 312,00 mil | -82,63 % |
Gastos operativos | 2,88 M | -64,76 % |
Ingresos netos | 3,87 M | 150,77 % |
Margen de beneficio neto | 1,24 mil | 392,27 % |
Beneficios por acción | -0,46 | 64,51 % |
EBITDA | -2,44 M | 64,22 % |
Tipo impositivo efectivo | -0,04 % | — |
Balance general
Activos totales
Responsabilidades totales
| (USD) | sept 2025info | Cambio interanual |
|---|---|---|
Efectivo y a corto plazo | 15,96 M | -20,02 % |
Activos totales | 26,09 M | -34,97 % |
Responsabilidades totales | 8,83 M | -68,31 % |
Patrimonio total | 17,25 M | — |
Acciones en circulación | 8,72 M | — |
Precio-valor contable | 7,23 | — |
Rentabilidad económica | -22,70 % | — |
Retorno sobre capital | -39,13 % | — |
Flujo de caja
Variación neta del flujo de caja
| (USD) | sept 2025info | Cambio interanual |
|---|---|---|
Ingresos netos | 3,87 M | 150,77 % |
Efectivo de operaciones | -3,33 M | 32,37 % |
Efectivo de inversión | 10,91 M | 441,12 % |
Efectivo de financiación | -10,34 M | -318,34 % |
Variación neta del flujo de caja | -2,70 M | -247,46 % |
Flujo de caja libre | -385,62 mil | -131,18 % |
Información sobre la empresa
Evogene is a computational chemistry company based in Israel, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries. At the core of its technology is ChemPass AI, a proprietary generative AI engine that enables the design of novel, highly potent small molecules optimized across multiple critical parameters. This powerful platform significantly improves success rates while reducing development time and costs. Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products driven by the integration of scientific innovation with real-world industry needs.
In 2024, the company began collaborating with Google Cloud to develop an AI-powered generative model aimed at discovering small molecules for drug development and sustainable agriculture. Wikipedia
Director ejecutivo
Fundación
1999
Sitio web
Empleados
117
